Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

Nexavar “Very Competitive” With Pfizer’s Sutent, Bayer Says

This article was originally published in The Pink Sheet Daily

  • News
  • Janet Aker

Executive Summary

Bayer’s kidney cancer drug brought in $25.2 mil. (€20 mil.) in the first quarter following its approval late last year.

You may also be interested in...



Bayer/Onyx Nexavar Hits Sales Plateau After Rapid Initial Uptake

Aggressive clinical trial plan aims to add new indications, build Nexavar oncology franchise on kidney cancer success.

Bayer/Onyx Nexavar Hits Sales Plateau After Rapid Initial Uptake

Aggressive clinical trial plan aims to add new indications, build Nexavar oncology franchise on kidney cancer success.

Wyeth CCI-779 Survival Benefit Over Interferon In Kidney Cancer May Warrant First-Line Use

CCI-779 (temsirolimus) monotherapy is associated with a 49% improvement in median overall survival compared to interferon in advanced renal cell carcinoma patients.

Table

View full table

Related Content

Pink Sheet
Pink Sheet

Topics

Tags:
BioPharmaceutical
Latest Headlines

China’s Public Payer Wants To Define Innovative Drugs As Those With ‘Novel Benefits’

Change Is Constant For Pneumococcal Vaccines: US CDC Prepares For Merck’s V116

Woodcock Takes On Rare Disease Challenges In Retirement, Keeps FDA, Industry At Arm’s Length

German HTA Queries Polivy Benefits Amid Lack Of Evidence

See All
UsernamePublicRestriction

Register

PS064190

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By